| 发明名称 | VEGF inhibition | ||
| 摘要 | The present invention provides methods for inhibiting VEGF production or secretion in a subject comprising administering to the subject an effective amount of a compound of Formula I. The invention also provides methods for the treatment or prevention of conditions associated with abnormal levels of VEGF production or secretion. | ||
| 申请公布号 | US8912225(B2) | 申请公布日期 | 2014.12.16 |
| 申请号 | US200511661460 | 申请日期 | 2005.08.31 |
| 申请人 | Pitney Pharmaceuticals Pty Limited | 发明人 | Morris David L.;Pourgholami Mohammad H. |
| 分类号 | A61K31/415;A61K31/4184;A61K31/427 | 主分类号 | A61K31/415 |
| 代理机构 | Kilpatrick Townsend & Stockton LLP | 代理人 | Kilpatrick Townsend & Stockton LLP |
| 主权项 | 1. A method for treating malignant ascites caused by ovarian cancer in a subject, the method comprising administering to the subject, who is suffering from malignant ascites caused by ovarian cancer, an effective amount of an albendazole wherein the effective amount is in the range of about 10 mg to about 200 mg per kg body weight per 24 hours, and wherein the administration is intracavitary. | ||
| 地址 | Sydney, NSW AU | ||